Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.46 |
| ▸ | FEN1 | P39748 | 1/20 | 0.46 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.46 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.45 |
| ▸ | CCR1 | P32246 | 1/20 | 0.45 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | CALCA | P06881 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MERTK | Q12866 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5643186 | 0.89 | KCNH2 (0.50) | KCNH2CYP2C9ERCC1FEN1ERCC4 | |
| SCHEMBL5538264 | 0.86 | MMP13 (0.45) | KCNH2CYP2C9KCNE1CCR1KCNQ1 | |
| SCHEMBL14567056 | 0.85 | KCNH2 (0.52) | KCNH2CYP2C9ERCC1FEN1ERCC4 | |
| SCHEMBL5548527 | 0.85 | CNR1 (0.43) | ALDH1A1MEN1KMT2A | |
| SCHEMBL5538308 | 0.82 | KCNH2 (0.51) | KCNH2CYP2C9ERCC1FEN1ERCC4 | |
| SCHEMBL1376535 | 0.80 | MAPT (0.61) | KCNH2CYP2C9CALCAGAAALDH1A1 | |
| SCHEMBL1750602 | 0.80 | MAPT (0.63) | KCNH2CYP2C9CALCAGAAALDH1A1 | |
| SCHEMBL1376994 | 0.79 | MAPT (0.60) | KCNH2CYP2C9CALCAGAAALDH1A1 | |
| SCHEMBL5533765 | 0.78 | KCNH2 (0.54) | KCNH2CYP2C9ERCC1FEN1ERCC4 | |
| SCHEMBL5537529 | 0.78 | KCNH2 (0.49) | KCNH2CYP2C9ERCC1FEN1ERCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050267132-A1 | Bicyclic heterocycles as HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-01 | — | — | US | claimed |
| US-7192948-B2 | Bicyclic heterocycles as HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-03-20 | — | — | US | disclosed |
| US-7192948-B2 | Bicyclic heterocycles as HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-03-20 | — | — | US | disclosed |
| US-7192948-B2 | Bicyclic heterocycles as HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-03-20 | — | — | US | disclosed |
| EP-1753767-A1 | BICYCLIC HETEROCYCLES AS HIV INTEGRASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2007-02-21 | — | — | EP | disclosed |
| WO-2005118589-A1 | BICYCLIC HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-15 | — | — | WO | disclosed |
| US-20050267132-A1 | Bicyclic heterocycles as HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267132-A1 | Bicyclic heterocycles as HIV integrase inhibitors | CCNI, TOP1, APOBEC3C | KCNH2 3080/4885CYP2C9 237/4885ERCC1 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.